Veritas Confirms Readiness for Human Trials of CTL-X for Pain; Projected to Start Early Next Month
November 08, 2018 08:30 ET
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that, despite the...
Veritas and Cannevert Complete Prestudy Visit of the Puerto Rico Clinical Trial Facility
December 29, 2017 03:05 ET
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that it has completed a prestudy...
Veritas’ Research Arm Cannevert Therapeutics Signs Letter of Intent with Fundación de Investigación (FDI) of Puerto Rico USA to Begin Human Trials of Its Lead Cannabis Strain for Pain
November 20, 2017 03:05 ET
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert...